Stock market announcement archive

August 22, 2023
Lifecare AS will present 1H 2023 financial and operational status in a webcastWednesday 23 August. The webcast will be for all shareholders and interestedparties at 09:30 - 10:15 CET.The Swedish research powered investment bank Redeye AB will host the webcast.Lifecare's CEO Joacim Holter presents the company's Semi Annual report followedby a Q&A with Redeye's analyst […]
Read more
July 18, 2023
Lifecare’s Sencell Continuous Glucose Monitoring (CGM) sensor has reached an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days). This achievement confirms the Sencell CGM technology potential and validates Lifecares expectation of a minimum 6-month sensor longevity. The longevity results were achieved by […]
Read more
June 27, 2023
Data from Lifecare's Clinical Development Study LFC-SEN-001 was presented at theAmerican Diabetes Association (ADA) Scientific Sessions 2023. Lifecare's posterpresentation reveals the study background, methods, and results. The resultsinclude an impressive mean average of absolute error (MARD) of 9,6%, positioningLifecares's Sencell technology with an accuracy that is acceptable fortherapeutic (medical) decisions such as insulin dose adjustments. […]
Read more
June 20, 2023
Data from Lifecare's Clinical Development Study LFC-SEN-001 confirm that theCompany's Continuous Glucose Monitoring (CGM) system (Sencell) has a solidclinical accuracy: the mean average of absolute error (MARD) between Sencell andmatched relative reference values was 9,6%. In context, regulatory authorities expect a MARD below 10% to acknowledge CGMfor therapeutic (medical) decisions such as insulin dose adjustments. […]
Read more
May 30, 2023
Lifecare, which is developing a long-lasting glucose sensor with the size of agrain of rice, is launching a new company called Lifecare Veterinary. Now man'sbest friend will also benefit from the same innovation. - Our main focus will still be the development of the sensor for people withdiabetes, increasing their quality of life. This is […]
Read more
May 12, 2023
Bergen, Norway 12 May 2023 Lifecare's latest updates include information of the recently finalized clinicalstudy and the presentation of study results on the upcoming American DiabetesAssociation Congress in San Diego, the company's Q1 2023 report, ISO 9001certification of Lifecare Laboratory and the progress for our plannedmanufacturing site in Mainz, Germany. Read more in Lifecare's newsletter […]
Read more
May 11, 2023
Today we can announce that we have finalized the Sencell Clinical Development Study (LFC-SEN-001) and it reveals accurate sensor performance in human subjects. - This is a very important step in the right direction to develop the next generation Continuous Glucose Monitor (CGM) for people with diabetes, says CEO Joacim Holter. In this first clinical […]
Read more
May 11, 2023
Lifecare AS will present Q1 2023 financial and operational status in a webcastThursday 11 May.The webcast will be for all shareholders and interested parties at 13:00 - 14:00CET. Lifecare CEO Joacim Holter will participate in the webcast. There will be aQ&A session following the presentation. The webcast will be available here:https://teams.microsoft.com/l/meetup-join/19%3ameeting_MDY4ZWM0YmMtOGJmMS00OGRlLTg0NGItOTRjNzM1NTNhNGM1%40thread.v2/0?context=%7b%22Tid%22%3a%22c5fbb1c6-4eb0-45db-9f3c-6e20ebcd710e%22%2c%22Oid%22%3a%2271082610-7009-40ed-92e6-70ae6bc35450%22%7d
Read more
April 27, 2023
In solemn circumstances yesterday late afternoon, Lifecare signed a lease fornew production facilities and a laboratory in Mainz, Germany. The letter ofintent entered into last autumn has thus been formalized with InnovationsparkMainz GmbH & Co KG.- The lease of production premises ensures modern and effective facilitiesneeded for Lifecares planned scale up of production, with necessary […]
Read more
April 11, 2023
Reference is made to Lifecare AS (LIFE) stock exchange notification 6 February2023.Today, Lifecare is pleased to announce that a sensor first used in our ongoingClinical Development Study has confirmed an operational longevity of 12 weeks ina continued laboratory (in vitro) set up. This is yet another importantmilestone in the development of our Sencell technology for […]
Read more